PTC Therapeutics (NASDAQ: PTCT) announced it was selected as the winning bidder to acquire ST-920, a one-time administered AAV gene ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE